Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The main objective is to evaluate the bronchodilatory efficacy, safety and pharmacokinetic
profiles of A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active
control, Proventil-HFA (Albuterol Metered Dose Inhaler (MDI)), and a Placebo DPI in
escalating and cumulative-doses up to 1440 mcg, eight (8) times of the proposed clinical
dose.